A multicentre, randomised trial of radioimmunotherapy with labetuzumab I-131, compared with post-operative chemotherapy or labetuzumab I-131 in combination with chemotherapy, in patients with liver metastases from colorectal cancer.

Trial Profile

A multicentre, randomised trial of radioimmunotherapy with labetuzumab I-131, compared with post-operative chemotherapy or labetuzumab I-131 in combination with chemotherapy, in patients with liver metastases from colorectal cancer.

Planning
Phase of Trial: Phase II

Latest Information Update: 21 May 2008

At a glance

  • Drugs Labetuzumab I 131 (Primary) ; Antineoplastics
  • Indications Cancer metastases; Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top